Novo Nordisk Korea releases research results for rapid-acting insulin

Novo Nordisk Korea said Thursday said that it has presented the results of ONSET, a clinical trial for rapid-acting mealtime insulin, Fiasp, at the International Congress of Diabetes and Metabolism 2018. The treatment is insulin that acts similar to endo http://www.koreabiomed.com/news/articleView.html?idxno=4361